{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:41:41Z","timestamp":1788878501418,"version":"build-2803163510"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2011,4,15]],"date-time":"2011-04-15T00:00:00Z","timestamp":1302825600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0018398","type":"journal-article","created":{"date-parts":[[2011,4,16]],"date-time":"2011-04-16T03:05:07Z","timestamp":1302923107000},"page":"e18398","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":103,"title":["Circulating FGF21 Levels Are Progressively Increased from the Early to End Stages of Chronic Kidney Diseases and Are Associated with Renal Function in Chinese"],"prefix":"10.1371","volume":"6","author":[{"given":"Zhuofeng","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoqiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenke","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,4,15]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1056\/NEJMe048211","article-title":"Chronic kidney disease predicts cardiovascular disease.","volume":"351","author":"TH Hostetter","year":"2004","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","article-title":"Prevalence of chronic kidney disease in the United States.","volume":"298","author":"J Coresh","year":"2007","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","article-title":"Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.","volume":"108","author":"MJ Sarnak","year":"2003","journal-title":"Circulation"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1681\/ASN.V1251079","article-title":"Left ventricular hypertrophy in the renal patient.","volume":"12","author":"RJ Middleton","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"9850","DOI":"10.1073\/pnas.93.18.9850","article-title":"Fibroblast growth factor (FGF) homologous factors: new members of the FGF family implicated in nervous system development.","volume":"93","author":"PM Smallwood","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1182\/blood.V97.11.3450","article-title":"Differential regulation of the fibroblast growth factor (FGF) family by alpha(2)-macroglobulin: evidence for selective modulation of FGF-2-induced angiogenesis.","volume":"97","author":"IR Asplin","year":"2001","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1046\/j.1524-475X.1996.40219.x","article-title":"Acidic fibroblast growth factor reduces renal morphologic and functional indicators of injury caused by ischemia and reperfusion.","volume":"4","author":"X Fu","year":"1996","journal-title":"Wound Repair Regen"},{"key":"ref8","first-page":"209","article-title":"Acidic fibroblast growth factor reduces rat skeletal muscle damage caused by ischemia and reperfusion.","volume":"108","author":"X Fu","year":"1995","journal-title":"Chin Med J (Engl)"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd2792","article-title":"The FGF family: biology, pathophysiology and therapy.","volume":"8","author":"A Beenken","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1507\/endocrj.KR07E-002","article-title":"Actions and mode of actions of FGF19 subfamily members.","volume":"55","author":"S Fukumoto","year":"2008","journal-title":"Endocr J"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1021\/mp700105z","article-title":"Mini-review: endocrine actions of fibroblast growth factor 19.","volume":"5","author":"S Jones","year":"2008","journal-title":"Mol Pharm"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0167-4781(00)00067-1","article-title":"Identification of a novel FGF, FGF-21, preferentially expressed in the liver.","volume":"1492","author":"T Nishimura","year":"2000","journal-title":"Biochim Biophys Acta"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","article-title":"FGF-21 as a novel metabolic regulator.","volume":"115","author":"A Kharitonenkov","year":"2005","journal-title":"J Clin Invest"},{"key":"ref14","first-page":"359","article-title":"FGF21: a novel prospect for the treatment of metabolic diseases.","volume":"10","author":"A Kharitonenkov","year":"2009","journal-title":"Curr Opin Investig Drugs"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1210\/en.2008-0816","article-title":"Fibroblast growth factor 21 corrects obesity in mice.","volume":"149","author":"T Coskun","year":"2008","journal-title":"Endocrinology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1210\/en.2006-1168","article-title":"The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21.","volume":"148","author":"A Kharitonenkov","year":"2007","journal-title":"Endocrinology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.cmet.2007.05.002","article-title":"Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states.","volume":"5","author":"MK Badman","year":"2007","journal-title":"Cell Metab"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.2337\/db07-1476","article-title":"Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans.","volume":"57","author":"X Zhang","year":"2008","journal-title":"Diabetes"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2265.2008.03502.x","article-title":"Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity.","volume":"71","author":"M Mraz","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1210\/jc.2008-2331","article-title":"Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects.","volume":"94","author":"H Li","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.metabol.2009.07.003","article-title":"Serum fibroblast growth factor 21 levels in gestational diabetes mellitus in relation to insulin resistance and dyslipidemia.","volume":"59","author":"S Stein","year":"2010","journal-title":"Metabolism"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e15534","DOI":"10.1371\/journal.pone.0015534","article-title":"Serum Levels of FGF-21 Are Increased in Coronary Heart Disease Patients and Are Independently Associated with Adverse Lipid Profile.","volume":"5","author":"Z Lin","year":"2010","journal-title":"PLoS One"},{"key":"ref23","article-title":"Serum fibroblast growth factor-21 concentration is associated with residual renal function and insulin resistance in end-stage renal disease patients receiving long-term peritoneal dialysis.","author":"SH Han","year":"2010"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2337\/dc08-1054","article-title":"Serum levels of the adipokine FGF21 depend on renal function.","volume":"32","author":"S Stein","year":"2009","journal-title":"Diabetes Care"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1161\/01.RES.81.5.679","article-title":"Trophic effect of human pericardial fluid on adult cardiac myocytes. Differential role of fibroblast growth factor-2 and factors related to ventricular hypertrophy.","volume":"81","author":"S Corda","year":"1997","journal-title":"Circ Res"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1161\/01.RES.0000162099.01268.d1","article-title":"Adenoviral gene transfer of FGF-5 to hibernating myocardium improves function and stimulates myocytes to hypertrophy and reenter the cell cycle.","volume":"96","author":"G Suzuki","year":"2005","journal-title":"Circ Res"},{"key":"ref27","first-page":"109","article-title":"Effect of basic fibroblast growth factor on left ventricular geometry in rats subjected to coronary occlusion and reperfusion.","volume":"4","author":"M Scheinowitz","year":"2002","journal-title":"Isr Med Assoc J"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.","volume":"359","author":"OM Gutierrez","year":"2008","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1681\/ASN.2005050573","article-title":"Fibroblast growth factor 23: roles in health and disease.","volume":"16","author":"EA Imel","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1681\/ASN.2006080936","article-title":"Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study.","volume":"18","author":"D Fliser","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.108.844506","article-title":"Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.","volume":"119","author":"OM Gutierrez","year":"2009","journal-title":"Circulation"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/0002-9149(86)90224-9","article-title":"Performance of primary and derived M-mode echocardiographic measurements for detection of left ventricular hypertrophy in necropsied subjects and in patients with systemic hypertension, mitral regurgitation and dilated cardiomyopathy.","volume":"57","author":"RB Devereux","year":"1986","journal-title":"Am J Cardiol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0002-9149(86)90771-X","article-title":"Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings.","volume":"57","author":"RB Devereux","year":"1986","journal-title":"Am J Cardiol"},{"key":"ref34","first-page":"1428","article-title":"Hypertension and left ventricular hypertrophy.","author":"Yang Yu","year":"2000"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.amjcard.2005.11.090","article-title":"N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients.","volume":"97","author":"IA Khan","year":"2006","journal-title":"Am J Cardiol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.jacc.2007.06.018","article-title":"The relationship between renal function and cardiac structure, function, and prognosis after myocardial infarction: the VALIANT Echo Study.","volume":"50","author":"A Verma","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1053\/j.ajkd.2009.01.004","article-title":"Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES).","volume":"53","author":"A Whaley-Connell","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"ref38","article-title":"Diabetes and kidney disease.","year":"2010"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1056\/NEJM200307313490517","article-title":"Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.","volume":"349","author":"Y Kida","year":"2003","journal-title":"N Engl J Med"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0929-6646(09)60104-2","article-title":"Dyslipidemia is associated with ventricular tachyarrhythmia in patients with acute ST-segment elevation myocardial infarction.","volume":"105","author":"YB Liu","year":"2006","journal-title":"J Formos Med Assoc"},{"key":"ref41","article-title":"Dyslipidemia is a strong predictor of myocardial infarction in subjects with chronic kidney disease.","author":"MJ Holzmann","year":"2010"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"F262","DOI":"10.1152\/ajprenal.00099.2005","article-title":"Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences.","volume":"290","author":"ND Vaziri","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.jrn.2010.05.010","article-title":"Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease.","volume":"20","author":"ND Vaziri","year":"2010","journal-title":"J Ren Nutr"},{"key":"ref44","first-page":"295","article-title":"The serum level and urinary excretion of beta2-microglobulin in health and renal disease.","volume":"26","author":"L Wibell","year":"1978","journal-title":"Pathol Biol (Paris)"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1159\/000113010","article-title":"Salivary beta2-microglobulin analysis in chronic kidney disease and hemodialyzed patients.","volume":"25","author":"R Michelis","year":"2007","journal-title":"Blood Purif"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1081\/JDI-120017475","article-title":"Serum cystatin C and beta2-microglobulin as markers of glomerular filtration rate.","volume":"25","author":"D Jovanovic","year":"2003","journal-title":"Ren Fail"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1097\/00029330-200807020-00001","article-title":"Prognostic values of serum cystatin C and beta2 microglobulin, urinary beta2 microglobulin and N-acetyl-beta-D-glucosaminidase in early acute renal failure after liver transplantation.","volume":"121","author":"ZQ Hei","year":"2008","journal-title":"Chin Med J (Engl)"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2337\/db08-0392","article-title":"Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice.","volume":"58","author":"J Xu","year":"2009","journal-title":"Diabetes"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0018398","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,21]],"date-time":"2021-11-21T19:56:20Z","timestamp":1637524580000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0018398"}},"subtitle":[],"editor":[{"given":"Aimin","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,4,15]]},"references-count":48,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2011,4,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0018398","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,15]]}}}